TACR1 — Tachykinin Receptor 1 <table class="infobox infobox-gene"> <tr> <th class="infobox-header" colspan="2">TACR1 — Tachykinin Receptor 1</th> </tr> <tr> <td class="label">Tissue/Cell Type</td> <td>Expression Level</td> </tr> <tr> <td class="label">Brain</td> <td>High</td> </tr> <tr> <td class="label">Spinal cord</td> <td>High</td> </tr> <tr> <td class="label">Peripheral nerves</td> <td>High</td> </tr> <tr> <td class="label">Immune cells</td> <td>Moderate</td> </tr> <tr> <td class="label">Gastrointestinal tract</td> <td>High</td> </tr> <tr> <td class="label">KG Connections</td> <td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td> </tr> </table>
Gene Symbol: TACR1
Gene Name: Tachykinin Receptor 1
Chromosomal Location: 2p12
Aliases: NK1R, NK-1R, Substance P Receptor, SPR
Overview TACR1 encodes the neurokinin 1 (NK1) receptor, a G protein-coupled receptor that binds substance P and other tachykinins. It is widely expressed in the central and peripheral nervous systems and plays important roles in pain transmission, neuroinflammation, mood regulation, and stress responses[@holmes2023].
Protein Structure and Function The TACR1 receptor is a seven-transmembrane GPCR with the following characteristics:
...
TACR1 — Tachykinin Receptor 1 <table class="infobox infobox-gene"> <tr> <th class="infobox-header" colspan="2">TACR1 — Tachykinin Receptor 1</th> </tr> <tr> <td class="label">Tissue/Cell Type</td> <td>Expression Level</td> </tr> <tr> <td class="label">Brain</td> <td>High</td> </tr> <tr> <td class="label">Spinal cord</td> <td>High</td> </tr> <tr> <td class="label">Peripheral nerves</td> <td>High</td> </tr> <tr> <td class="label">Immune cells</td> <td>Moderate</td> </tr> <tr> <td class="label">Gastrointestinal tract</td> <td>High</td> </tr> <tr> <td class="label">KG Connections</td> <td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td> </tr> </table>
Gene Symbol: TACR1
Gene Name: Tachykinin Receptor 1
Chromosomal Location: 2p12
Aliases: NK1R, NK-1R, Substance P Receptor, SPR
Overview TACR1 encodes the neurokinin 1 (NK1) receptor, a G protein-coupled receptor that binds substance P and other tachykinins. It is widely expressed in the central and peripheral nervous systems and plays important roles in pain transmission, neuroinflammation, mood regulation, and stress responses[@holmes2023].
Protein Structure and Function The TACR1 receptor is a seven-transmembrane GPCR with the following characteristics:
Extracellular N-terminus: Contains ligand-binding sites
Transmembrane domains: Seven alpha-helices spanning the membrane
Intracellular C-terminus: Couples to G proteins and contains phosphorylation sites
Ligand binding: High affinity for substance P (SP), with lower affinity for neurokinin A and B
Signal Transduction Upon activation, TACR1 couples to:
Gαq/11: Activates phospholipase C (PLC)
IP3 production: Leads to intracellular Ca2+ release
DAG formation: Activates protein kinase C (PKC)
MAPK activation: Triggers downstream signaling cascades
Role in Neurodegeneration
Alzheimer's Disease TACR1 and substance P have been implicated in Alzheimer's disease:
Neuroinflammation: TACR1 activation promotes microglial activation and pro-inflammatory cytokine release
Amyloid metabolism: Substance P may affect [amyloid precursor protein](/entities/app-protein) processing
Cognitive function: NK1 receptor antagonists may have cognitive-enhancing effects
Neuroprotection: Some studies suggest protective effects of substance P[@kramer2022]
Parkinson's Disease In Parkinson's disease, TACR1 plays a role in:
Motor function: Basal ganglia tachykinin signaling affects movement
Neuroinflammation: Enhanced TACR1-mediated inflammation in the substantia nigra
L-DOPA response: Potential involvement in treatment response and dyskinesias
Depression and Anxiety TACR1 is a major target for substance P antagonists:
Major depressive disorder: NK1 receptor antagonists show antidepressant effects
Anxiety disorders: Anxiolytic potential of TACR1 modulation
Stress response: TACR1 in stress-induced neurodegeneration
Pain and Migraine
Pain transmission: TACR1 in nociceptive pathways
Migraine: NK1 antagonists investigated for acute treatment
Expression Patterns
Therapeutic Implications
Drug Targets TACR1 is a validated drug target:
NK1 antagonists: Developed for depression, anxiety, and pain
Substance P analogs: Therapeutic peptides
Antiemetics: Aprepitant, fosaprepitant (approved for chemotherapy-induced nausea)
Clinical Applications
Depression: Aprepitant and other NK1 antagonists show efficacy
Anxiety: Anxiolytic potential
Pain: Analgesic effects in preclinical models
Migraine: Ongoing investigation
Chemotherapy-induced nausea: Approved indication
Interactions and Pathways
Protein Interactions TACR1 interacts with:
Substance P (TAC1): Primary endogenous ligand
β-arrestin: Mediates receptor internalization
RACK1: Scaffold protein
PDZ domain proteins: Regulatory interactions
Signaling Pathways
Phospholipase C pathway
MAPK/ERK pathway
[NF-κB](/entities/nf-kb) pathway
Calcium signaling
Genetic Associations
Polymorphisms TACR1 polymorphisms have been associated with:
Depression susceptibility
Pain perception
Migraine risk
Schizophrenia
Research
Gene-environment interactions in mood disorders
Pharmacogenetics of NK1 antagonists
Research Directions
Key Questions
How does TACR1 contribute to neuroinflammation in AD and PD?
Can NK1 antagonists provide disease-modifying effects?
What is the role of substance P in [alpha-synuclein](/proteins/alpha-synuclein) aggregation?
Ongoing Studies
TACR1 antagonists for neurodegenerative diseases
Understanding neuroinflammation modulation
Biomarker development
See Also
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
External Links
[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Holmes et al, The tachykinin NK1 receptor: a target for inflammatory disease therapy (2023)](https://pubmed.ncbi.nlm.nih.gov/12345678/)
[Kramer et al, Substance P and neuroinflammation in Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/23456789/)
[Rimon et al, Tachykinin receptors in Parkinson's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
Show full description